What is Inotrem?
Inotrem is a specialized biotechnology firm dedicated to the development of innovative therapies that target the TREM-1 pathway. By focusing on restoring immune balance in life-threatening inflammatory conditions, the company addresses severe medical challenges such as septic shock and acute respiratory distress. Their lead product, nangibotide, represents a first-in-class peptidic inhibitor designed to mitigate dysregulated immune responses. Furthermore, Inotrem distinguishes itself through a strategic partnership with Roche Diagnostics, providing a companion diagnostic tool that enhances patient stratification and therapeutic precision. This integrated approach positions the company at the forefront of precision medicine within the critical care landscape.
How much funding has Inotrem raised?
Inotrem has raised a total of $85.6M across 2 funding rounds:
Series A
$21.8M
Series B
$63.7M
Series A (2014): $21.8M with participation from Sofinnova Partners, Edmond de Rothschild, and Transfert Initiative
Series B (2020): $63.7M led by Invus, Bpifrance, Kreos Capital, Morningside Ventures, Andera Partners, BiomedInvest, Sofinnova Partners, and Fountain Healthcare Partners
Key Investors in Inotrem
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Invus
An investment firm specializing in financial advice, investment services, and consulting services with a long-standing history since 1985.
Kreos Capital
A London-based firm specializing in finance, providing investment services and business management to high-growth companies.
What's next for Inotrem?
Looking ahead, Inotrem is poised to leverage its recent capital infusion to accelerate the clinical development of its lead asset, nangibotide. The company's strategic roadmap emphasizes the expansion of its therapeutic reach into broader inflammatory indications, supported by the continued validation of its companion diagnostic platform. As the firm moves deeper into its lifecycle, the focus will likely shift toward regulatory engagement and potential commercialization pathways. By maintaining its commitment to scientific rigor and strategic partnerships, Inotrem aims to solidify its market position and deliver transformative outcomes for patients suffering from acute inflammatory syndromes.
See full Inotrem company page
